203 related articles for article (PubMed ID: 8922563)
1. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension.
Patel SS; Spencer CM
Drugs Aging; 1996 Nov; 9(5):363-78. PubMed ID: 8922563
[TBL] [Abstract][Full Text] [Related]
2. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
3. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
4. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension.
Fingeret M; Gaddie IB; Bloomenstein M
Clin Exp Optom; 2019 Nov; 102(6):541-550. PubMed ID: 30614563
[TBL] [Abstract][Full Text] [Related]
5. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
6. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.
Li N; Chen XM; Zhou Y; Wei ML; Yao X
Clin Exp Ophthalmol; 2006 Nov; 34(8):755-64. PubMed ID: 17073898
[TBL] [Abstract][Full Text] [Related]
7. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
Mastropasqua L; Carpineto P; Ciancaglini M; Gallenga PE
Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
[TBL] [Abstract][Full Text] [Related]
8. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
[TBL] [Abstract][Full Text] [Related]
9. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension.
Orme M; Collins S; Dakin H; Kelly S; Loftus J
Curr Med Res Opin; 2010 Mar; 26(3):511-28. PubMed ID: 20014995
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
García Sanchez J
Eur J Ophthalmol; 2000; 10(3):198-204. PubMed ID: 11071026
[TBL] [Abstract][Full Text] [Related]
11. Preservative-free latanoprost eye drops in patients with primary open-angle glaucoma/ocular hypertension.
Sanford M
Clin Drug Investig; 2014 Jul; 34(7):521-8. PubMed ID: 24895141
[TBL] [Abstract][Full Text] [Related]
12. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.
Lewis RA; Levy B; Ramirez N; Kopczynski CC; Usner DW; Novack GD;
Br J Ophthalmol; 2016 Mar; 100(3):339-44. PubMed ID: 26209587
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study.
Chiseliţă D; Antohi I; Medvichi R; Danielescu C
Oftalmologia; 2005; 49(3):39-45. PubMed ID: 16408674
[TBL] [Abstract][Full Text] [Related]
14. Effects of latanoprost 50 micrograms/ml on Chinese patients with primary open-angle glaucoma and ocular hypertension.
Liu CJ; Chou JC; Hsu WM; Liu JH
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Oct; 62(10):703-9. PubMed ID: 10533300
[TBL] [Abstract][Full Text] [Related]
15. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
Kałuzny J; Sobecki R; Czechowicz-Janicka K; Kecik D; Kałuzny BJ; Stewart JA; Stewart WC
Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
Uusitalo H; Pillunat LE; Ropo A;
Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
[TBL] [Abstract][Full Text] [Related]
19. A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension.
Eisenberg DL; Camras CB
Drug Saf; 1999 Jun; 20(6):505-14. PubMed ID: 10392667
[TBL] [Abstract][Full Text] [Related]
20. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost.
Traverso CE; Ropo A; Papadia M; Uusitalo H
J Ocul Pharmacol Ther; 2010 Feb; 26(1):97-104. PubMed ID: 20148656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
